STC-15 is an orally bioavailable inhibitor of the RNA methyltransferase METTL3. Inhibits acute myeloid leukemia growth and induces anti-cancer immunity via activation of double strand RNA sensing machinery and interferon signaling. STC-15 synergizes with radiation therapy and T cell checkpoint blockade and enhances the cytotoxicity of doxorubicin chemotherapy.
* VAT and and shipping costs not included. Errors and price changes excepted